Nondystrophic myotonia: challenges and future directions.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Experimental Neurology

• Publication date

  2014-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.expneurol.2013.12.005PMID 24361411PMCID PMC4078724
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Non-dystrophic myotonia: prospective study of objective and patient reported outcomes.

  2013cited by this paper
• Functional characterization of ClC-1 mutations from patients affected by recessive myotonia congenita presenting with different clinical phenotypes☆

  2013influential reference
• Mexiletine for treatment of myotonia: a trial triumph for rare disease networks.

  2012cited by this paper
• Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial.

  2012cited by this paper
• Measuring quality of life impairment in skeletal muscle channelopathies

  2012cited by this paper
• Role of disease severity, illness perceptions, and mood on quality of life in muscle disease

  2012cited by this paper
• Low-Rate Repetitive Nerve Stimulation Protocol in an Italian Cohort of Patients Affected by Recessive Myotonia Congenita

  2011cited by this paper
• The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment.

  2010cited by this paper
• Ranolazine selectively blocks persistent current evoked by epilepsy‐associated NaV1.1 mutations

  2010cited by this paper
• Skeletal muscle channelopathies: nondystrophic myotonias and periodic paralysis.

  2010cited by this paper
• Redefining the clinical phenotypes of non-dystrophic myotonic syndromes

  2009cited by this paper
• Use-dependent block of cardiac late Na(+) current by ranolazine.

  2009cited by this paper
• The Investigational Anticonvulsant Lacosamide Selectively Enhances Slow Inactivation of Voltage-Gated Sodium Channels

  2008cited by this paper
• State- and Use-Dependent Block of Muscle Nav1.4 and Neuronal Nav1.7 Voltage-Gated Na+ Channel Isoforms by Ranolazine

  2008cited by this paper
• Block of Tetrodotoxin-sensitive, Nav1.7, and Tetrodotoxin-resistant, Nav1.8, Na+ channels by Ranolazine

  2008cited by this paper
• F413C and A531V but not R894X myotonia congenita mutations cause defective endoplasmic reticulum export of the muscle‐specific chloride channel CLC‐1

  2008cited by this paper
• Chloride channel myotonia: exon 8 hot-spot for dominant-negative interactions.

  2007influential reference
• Pathomechanisms in channelopathies of skeletal muscle and brain.

  2006cited by this paper
• Drug treatment for myotonia.

  2006cited by this paper
• Phenotypic variability in myotonia congenita

  2005cited by this paper
• Correlating phenotype and genotype in the periodic paralyses

  2004cited by this paper
• Spectrum of CLCN1 mutations in patients with myotonia congenita in Northern Scandinavia

  2001cited by this paper
• Spectrum of CLCN1 mutations in patients with myotonia congenita in Northern Scandinavia

  2001cited by this paper
• Molecular mechanisms of ion conduction in ClC-type chloride channels: lessons from disease-causing mutations.

  2000cited by this paper
• The Muscle Chloride Channel ClC-1 Has a Double-Barreled Appearance that Is Differentially Affected in Dominant and Recessive Myotonia

  1999cited by this paper
• Founder mutations and the high prevalence of myotonia congenita in northern Finland

  1999cited by this paper
• Channelopathies: the nondystrophic myotonias and periodic paralyses.

  1996cited by this paper
• Mutations in the human skeletal muscle chloride channel gene (CLCN1) associated with dominant and recessive myotonia congenita

  1996cited by this paper
• Spectrum of mutations in the major human skeletal muscle chloride channel gene (CLCN1) leading to myotonia.

  1995cited by this paper
• Mutations in dominant human myotonia congenita drastically alter the voltage dependence of the CIC-1 chloride channel.

  1995cited by this paper
• Nonsense and missense mutations of the muscle chloride channel gene in patients with myotonia congenita.

  1994cited by this paper
• Molecular basis of Thomsen's disease (autosomal dominant myotonia congenita)

  1993cited by this paper
• Duchenne-Becker muscular dystrophy and the nondystrophic myotonias. Paradigms for loss of function and change of function of gene products.

  1993cited by this paper
• Periodic paralysis, myotonia congenita and sarcolemmal ion channels: a success of the candidate gene approach.

  1993cited by this paper
• Genetics and physiology of the myotonic muscle disorders.

  1993cited by this paper
• Treatment of myotonia with antiarrhythmic drugs

  1992cited by this paper
• Identification of a mutation in the gene causing hyperkalemic periodic paralysis.

  1991cited by this paper
• Population frequencies of inherited neuromuscular diseases--a world survey.

  1991cited by this paper
• AAEE minimonograph #27: Differential diagnosis of myotonic syndromes

  1987cited by this paper
• Myotonia congenita and myotonic dystrophy: Descriptive epidemiological investigation in Turin, Italy (1955–1979)

  1982cited by this paper
• Cardiac conduction in myotonic dystrophy.

  1975cited by this paper
• On the repetitive discharge in myotonic muscle fibres

  1974cited by this paper
• Chloride conductance in normal and myotonic muscle fibres and the action of monocarboxylic aromatic acids

  1971cited by this paper
• The treatment of myotonia: a controlled clinical trial.

  1959cited by this paper
• Source (or Part of the following Source): Type Article Title Redefining the Clinical Phenotypes of Non-dystrophic Myotonic Syndromes Author(s)

  year unknowncited by this paper

• Biophysical and structural insights into the SCN4A E452K variant linked to myotonia and paramyotonia congenita

  2025cites this paper
• Phenotypic Variations in Clinical Presentations of Paramyotonia Congenita in Two Brothers

  2025cites this paper
• Plateau potentials contribute to myotonia in mouse models of myotonia congenita.

  2022cites this paper
• Impact of restricted access to, and low awareness of, mexiletine on people with myotonia: a real-world European survey.

  2022cites this paper
• Myotonia Congenita: Clinical Characteristic and Mutation Spectrum of CLCN1 in Chinese Patients

  2021cites this paper
• Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel

  2021cites this paper
• Skeletal muscle ClC-1 chloride channels in health and diseases

  2020cites this paper
• The mechanism underlying transient weakness in myotonia congenita

  2020cites this paper
• Genotype-Phenotype Correlations and Characterization of Medication Use in Inherited Myotonic Disorders

  2020cites this paper
• TRPV4 Antagonism Prevents Mechanically Induced Myotonia

  2020cites this paper
• CLCN1 Molecular Characterization in 19 South-Italian Patients With Dominant and Recessive Type of Myotonia Congenita

  2020cites this paper
• Novel pathomechanisms and disease associations of the voltage-gated sodium channel NaV1.4

  2019cites this paper
• Treatment of myotonia congenita with retigabine in mice

  2019cites this paper
• A role for cannabinoids in the treatment of myotonia? Report of compassionate use in a small cohort of patients

  2019cites this paper
• Central Role of Subthreshold Currents in Myotonia

  2019cites this paper
• Mapping ligand binding pockets in chloride ClC‐1 channels through an integrated in silico and experimental approach using anthracene‐9‐carboxylic acid and niflumic acid

  2018cites this paper
• Nondystrophic Myotonic Disorders

  2018cites this paper
• Neuromuscular Disorders

  2018cites this paper
• Elevation of extracellular osmolarity improves signs of myotonia congenita in vitro: a preclinical animal study

  2018cites this paper
• Title A Sodium Channel Myotonia Presenting with Intermittent Dysphagia as a Manifestation of a Rare SCN 4 A Variant Permalink

  2017cites this paper
• Open-label trial of ranolazine for the treatment of myotonia congenita

  2017cites this paper
• Inhibiting persistent inward sodium currents prevents myotonia

  2017cites this paper
• Persistent Inward Currents Play a Role in Muscle Dysfunction Seen inMyotonia Congenita

  2017cites this paper
• Targeted Next Generation Sequencing in patients with Myotonia Congenita.

  2017cites this paper
• A Sodium Channel Myotonia Presenting with Intermittent Dysphagia as a Manifestation of a Rare SCN4A Variant

  2017cites this paper
• THE NONDYSTROPHIC MYOTONIAS (CLINICAL CASE, DISCUSSION)

  2016cites this paper
• Genetic and molecular studies of skeletal muscle channelopathies

  2016cites this paper
• Multidisciplinary study of a new ClC-1 mutation causing myotonia congenita: a paradigm to understand and treat ion channelopathies

  2016cites this paper
• The course and outcome of pregnancy in women with nondystrophic myotonias

  2015cites this paper
• Myotonia congenita: novel mutations in CLCN1 gene

  2015cites this paper
• Effect of mexiletine on transitory depression of compound motor action potential in recessive myotonia congenita.

  2015cites this paper
• ClC-1 chloride channels: state-of-the-art research and future challenges

  2015cites this paper
• ClC‐1 mutations in myotonia congenita patients: insights into molecular gating mechanisms and genotype–phenotype correlation

  2015cites this paper
• Sodium channel slow inactivation as a therapeutic target for myotonia congenita

  2015influential citation
• Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs

  2014cites this paper